Clinical Trial Update: Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant lenvatinib combined with transarterial chemoembolization (TACE) for transplant-eligible patients with large hepato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Transarterial chemoembolization (chemotherapy with embolization (various agents))

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ENROLLING_BY_INVITATION